• Profile
Close

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): A multicentre, single-drug, prospective, non-randomised phase 2 trial

The Lancet Respiratory Medicine Jun 03, 2018

Schöffski P, et al. - Considering the observation that the inflammatory myofibroblastic tumour (IMFT), a rare mesenchymal neoplasm, is characterised by anaplastic lymphoma kinase (ALK) gene rearrangements, researchers investigated crizotinib, a tyrosine kinase inhibitor, for its activity and safety regarding targeting ALK in patients with advanced IMFT either with or without ALK alterations. In this trial, with 50% of participants with ALK-positive tumours achieving an objective response, crizotinib met the prespecified criteria for success. Results supported the rationale for inhibiting ALK in patients with IMFT. For patients with locally advanced or metastatic ALK-positive IMFT who do not qualify for curative surgery, crizotinib could be considered as the standard of care.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay